Beam Q2 net loss $72M; BEAM-201 IND on clinical hold; cash $1.2B

Beam Therapeutics Inc.

2022-Q2 EPS reported -$2.03 revenue$25,084,000

Net loss $72.0M ($1.02/share) vs $76.3M ($1.23) prior year; R&D spend $74.6M (+64% YoY).
BEAM-201 IND placed on clinical hold by FDA July 29; awaiting official letter.
Patient enrollment in BEACON Phase 1/2 for BEAM-101 on track for 2H 2022.
John Lo, Ph.D., appointed Chief Commercial Officer; Amended Verve deal adds CV target.
Cash, cash equivalents and marketable securities $1.2B as of June 30, 2022.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.